Replies to post #336 on Equity Field Notes from temporal sources

[DanWebzster]

ZIOP has been developing a novel CAR-T platform and an IL-2 platform (gene therapy for solid tumors )

6/18 FDA placed a clinical hold on Ph1 CAR-T trial for relapsed/refractory leukemia/lymphoma.

At ASCO, ZIOP presented survival data from a Ph1 combo (IL-2 + Veledimex) study. Overall survival was 12.7 months for this injection therapy.

There is much skepticism regarding intratumoral injection therapies.

Cash runway does not extend thru H1/19.

I won't touch this during tax loss season.